Accessibility Menu
CellaVision Ab (publ) logo

CellaVision Ab (publ)(OTC) CLVSF

Current Price$14.00
Market Cap$333.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+687%
5 Year-57%
1 Year-26%
1 Month+6%
CellaVision Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 14.002026-06-23
CellaVision Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.12%USD 13.192026-05-15
1 month+6.12%USD 13.192026-05-15
3 month-11.28%USD 15.782026-03-12
Year to date-14.92%USD 16.462025-11-11
1 year-25.75%USD 18.852025-05-29
3 year-15.25%USD 16.522023-05-19
5 year-56.55%USD 32.222021-04-06
Since inception+686.51%USD 1.782010-06-23

CellaVision Ab (publ) Financials at a Glance

Market Cap

$333.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 737.44M

Net Income (TTM)

SEK 128.81M

EPS (TTM)

$0.58

P/E Ratio

24.25

Dividend

$0.30

Beta (Volatility)

-0.01 (Low)

Price

$14.00

Volume

1,740

Open

$14.00

Previous Close

$14.00

Daily Range

$14.00 - $14.00

52-Week Range

$13.49 - $19.28

Estimated Earnings Date

Oct 29, 2026

CLVSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CellaVision Ab (publ)

CellaVision AB (publ) is a Swedish company founded in 1994, specializing in digital analytical solutions for blood and body fluid samples. With a strong global presence, CellaVision serves healthcare services across multiple regions, including Europe, the Americas, and Asia Pacific.

Products and Services
  • CellaVision DM1200 and DM9600 for automated image capture
  • CellaVision Peripheral Blood Application for standardized blood smear analysis
  • CellaVision Remote Review Software for collaborative smear review
Growth Outlook
  • Revenue increased to SEK 198.2 million in Q2 2026, up from SEK 166.4 million in Q1 2026
  • Net income rose to SEK 32.4 million in Q2 2026, reflecting strong operational performance
  • Operating income margin improved to 20.6% in Q2 2026, indicating efficient cost management
Financial Highlights
  • Trailing twelve-month revenue of SEK 1.1 billion, showcasing consistent growth
  • Net profit margin of 18.4% for the trailing twelve months, indicating profitability
  • Cash and cash equivalents of SEK 170.7 million as of June 30, 2026, ensuring liquidity
CellaVision AB (publ) is positioned in the medical devices industry, focusing on innovative solutions that enhance laboratory efficiency and accuracy. The company's advanced products, such as the CellaVision DM1200 and specialized software applications, cater to the evolving needs of diagnostic laboratories. Recent financial performance highlights a robust growth trajectory, with significant increases in revenue and net income, reflecting the company's operational effectiveness. The strong cash position further supports future investments and strategic initiatives. CellaVision's commitment to innovation and quality positions it well for continued success in the healthcare sector.
AI Generated • Jul 22, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

251

CEO

Steve Ferguson

Website

www.cellavision.com

Headquarters

Lund, SN 223 62, SE

CLVSF Financials

Key Financial Metrics (TTM)

Gross Margin

68.71%

Operating Margin

22.23%

Net Income Margin

17.46%

Return on Equity

14.59%

Return on Capital

22.13%

Return on Assets

11.30%

Earnings Yield

4.12%

Dividend Yield

2.12%

Payout Ratio

50.81%

Stock Overview

Market Cap

$333.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.85M

Volume

1.74K

Avg. Volume

28.177

Financials (TTM)

Gross Profit

SEK 506.66M

Operating Income

SEK 163.99M

EBITDA

SEK 188.13M

Operating Cash Flow

SEK 172.34M

Capital Expenditure

-SEK 59.32M

Free Cash Flow

SEK 113.02M

Cash & ST Invst.

SEK 170.71M

Total Debt

SEK 51.83M

CellaVision Ab (publ) Performance Analysis

CellaVision Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 63,176,555-4.1%
20232023-12-31SEK 63,799,5081.0%
20242024-12-31SEK 68,403,9927.2%
20252025-12-31SEK 77,386,42013.1%
CellaVision Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-8.2%
Q42025-12-3112.3%
Q12026-03-31-15.6%
Q22026-06-3019.1%
CellaVision Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 0.49-19.9%
20232023-12-31SEK 0.515.0%
20242024-12-31SEK 0.568.4%
20252025-12-31SEK 0.6517.3%
CellaVision Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-17.1%
Q42025-12-3136.6%
Q12026-03-31-47.5%
Q22026-06-3043.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 198.18M

+3.6%

Gross Profit

SEK 139.57M

+7.7%

Gross Margin

70.43%

N/A

Market Cap

$333.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.39M

N/A

Employees

241

N/A

Net Income

SEK 32.35M

-14.0%

EBITDA

SEK 54.10M

+1.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 170.71M

+9.9%

Total Debt

SEK 51.83M

+71.8%

Accounts Receivable

SEK 134.89M

-0.8%

Inventory

SEK 128.08M

+10.9%

Long Term Debt

SEK 35.90M

+145.1%

Short Term Debt

SEK 15.93M

+2.7%

Return on Assets

11.30%

N/A

Return on Invested Capital

16.27%

N/A

Free Cash Flow

SEK 26.12M

-21.4%

Operating Cash Flow

SEK 28.86M

-50.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CALZFPolynovo Limited
$0.59-2.14%
BOIRFBoiron S.A.
$31.50+0.00%
GSGTFGenSight Biologics S.A.
$0.09+0.00%
AVNBFAvon Technologies Plc
$22.49+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About CLVSF

What is the current price of CellaVision Ab (publ)?

CellaVision Ab (publ) is trading at $14.00 per share.

What is the 52-week range for CellaVision Ab (publ)?

Over the past 52 weeks, CellaVision Ab (publ) has traded between $13.49 and $19.28.

How much debt does CellaVision Ab (publ) have?

As of the most recent reporting period, CellaVision Ab (publ) reported total debt of SEK 5.40M.

How much cash does CellaVision Ab (publ) have on hand?

CellaVision Ab (publ) reported SEK 17.79M in cash and cash equivalents in its most recent financial results.

What is CellaVision Ab (publ)’s dividend yield?

CellaVision Ab (publ) currently has a dividend yield of 2.12%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services